---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-005552"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2024-05-03T23:59:59+00:00"
generated_at: "2026-06-02T23:12:26.496715+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences receives Nasdaq bid price deficiency notice; has until Oct 30 to regain compliance

## Summary
- Received Nasdaq notice on May 3, 2024 for closing bid price below $1.00 for 30 consecutive trading days.
- Has 180 calendar days, until October 30, 2024, to regain compliance with Minimum Bid Price Requirement.
- To cure: bid price must close at or above $1.00 for at least 10 consecutive business days before deadline.
- If not cured by Oct 30, may qualify for additional 180-day period if it meets other listing standards.
- Company intends to monitor bid price and consider options including a potential reverse stock split.

## SEC filing metadata
- accession: 0001654954-24-005552
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2024-05-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495424005552/0001654954-24-005552-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495424005552/ndra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-005552
- JSON: https://secwatch.observer/filing/0001654954-24-005552.json
- Plain text: https://secwatch.observer/filing/0001654954-24-005552.txt

## Key facts
- Listing & Compliance Notices
  ENDRA Life Sciences Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: May 3, 2024, ENDRA Life Sciences Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The notification has no immediat
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000165495424005552/0001654954-24-005552-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.